Cargando…

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non‐HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk–benefit pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pipe, Steven W., Kruse‐Jarres, Rebecca, Mahlangu, Johnny N., Pierce, Glenn F., Peyvandi, Flora, Kuebler, Peter, De Ford, Christian, Sanabria, Fabián, Ko, Richard H., Chang, Tiffany, Hay, Charles R. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756842/ https://www.ncbi.nlm.nih.gov/pubmed/33331042 http://dx.doi.org/10.1111/jth.15186

Ejemplares similares

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
por: Callaghan, Michael U., et al.
Publicado: (2022)

Mortality in congenital hemophilia A – a systematic literature review
por: Hay, Charles R. M., et al.
Publicado: (2020)

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
por: Kruse-Jarres, Rebecca, et al.
Publicado: (2022)

Acquired hemophilia A: emerging treatment options
por: Janbain, Maissaa, et al.
Publicado: (2015)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH
por: van Galen, Karin P. M., et al.
Publicado: (2021)

Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis
por: Pipe, Steven W., et al.
Publicado: (2023)

Balance, falls, and exercise: Beliefs and experiences in people with hemophilia: A qualitative study
por: Flaherty, Lorraine M., et al.
Publicado: (2017)

Product type and other environmental risk factors for inhibitor development in severe hemophilia A
por: Peyvandi, Flora, et al.
Publicado: (2018)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study
por: Barnes, Richard F. W., et al.
Publicado: (2016)

Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
por: Abbattista, Maria, et al.
Publicado: (2021)

Updates on Novel Non-Replacement Drugs for Hemophilia
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Identification of patients with congenital hemophilia in a large electronic health record database
por: Wang, Michael, et al.
Publicado: (2017)

Mild and Moderate Hemophilia A: Neglected Conditions, Still with Unmet Needs
por: Castaman, Giancarlo, et al.
Publicado: (2023)

HCV Genotypes of People with Hemophilia in Countries with High Seroprevalances
por: Mahlangu, J N, et al.
Publicado: (2011)

Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review
por: Shapiro, Amy D., et al.
Publicado: (2022)

A Case of Acquired Hemophilia A and Congenital Hemophilia B
por: Fortier, Julia C, et al.
Publicado: (2022)

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009)

Handwriting Analysis in Children and Adolescents with Hemophilia: A Pilot Study
por: Pasta, Gianluigi, et al.
Publicado: (2020)

The role of point-of-Care Musculoskeletal Ultrasound for Routine Joint evaluation and management in the Hemophilia Clinic - A Real World Experience
por: Gallastegui, N, et al.
Publicado: (2022)

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries
por: Gupta, Naresh, et al.
Publicado: (2019)

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A
por: Klamroth, Robert, et al.
Publicado: (2022)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Establishing an online physical exercise program for people with hemophilia
por: Wagner, Barbara, et al.
Publicado: (2019)

Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity
por: Donadon, Irving, et al.
Publicado: (2018)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy
por: Pipe, Steven W., et al.
Publicado: (2023)

Recombinant single‐chain factor VIII in severe hemophilia: Long‐term safety and efficacy in previously treated patients in the AFFINITY extension study
por: Mahlangu, Johnny, et al.
Publicado: (2022)

Editorial: Modern Approaches to Hemophilia Management: Gene Therapy and Beyond
por: Coriu, Daniel, et al.
Publicado: (2022)

Implementing immunization program efficiently, and establishing national database of adverse reactions
por: Gao, George Fu
Publicado: (2014)

A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect
por: Garagiola, Isabella, et al.
Publicado: (2015)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies
por: Parnes, Aric, et al.
Publicado: (2021)

Identification and Validation of Hemophilia-Related Outcomes on Japanese Electronic Medical Record Database (Hemophilia-REAL V Study)
por: Fujiwara, Takashi, et al.
Publicado: (2021)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia
por: Badescu, Minerva Codruta, et al.
Publicado: (2022)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies
por: Chowdary, Pratima, et al.
Publicado: (2022)

Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B
por: Schmidt, Manfred, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t49buv7ch27m74gfl72fgnmp7r